Peter Junker - Concepedia

Author

Peter Junker

Also Known As

INSERM, Junker, P, Junker, P., Junker, Peter, K. Stengaard-Pedersen, P JUNKER, P Junker, P. JUNKER, P. Junker, PETER JUNKER

341

Publications

6.3K

Citations

H-Index

100

Concepts

All Affiliations

Odense University Hospital University of Southern Denmark Aarhus University Hospital University of Copenhagen Rigshospitalet

About

Peter Junker is an author at Odense University Hospital specializing in medicine, rheumatology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	932
2	Health Sciences	2	2	62
3	Public Health	2	2	144
4	Engineering	1	1	58
5	Management	1	1	47

Peter Junker

119

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA) Merete Lund Hetland, B Ejbjerg, Kim Hørslev‐Petersen, Annals of the Rheumatic Diseases	2008	364
Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker, Annals of the Rheumatic Diseases	2010	188
Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator‐initiated, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study Merete Lund Hetland, Kristian Stengaard‐Pedersen, Peter Junker, Arthritis & Rheumatism	2006	172
A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets Søren Jacobsen, Jørgen Holm Petersen, Susanne Ullman, Clinical Rheumatology RheumatologyClinical FindingAutoimmune DiseaseSystemic Lupus ErythematosusAllergy	1998	156
HLA‐G genotype and HLA‐G expression in systemic lupus erythematosus: HLA‐G as a putative susceptibility gene in systemic lupus erythematosus Roberta Rizzo, Thomas Vauvert F. Hviid, Marcello Govoni, Tissue Antigens	2008	126
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial Kim Hørslev‐Petersen, Merete Lund Hetland, Peter Junker, Annals of the Rheumatic Diseases	2013	124
Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker, Annals of the Rheumatic Diseases	2007	124
YKL‐40, a Matrix Protein of Specific Granules in Neutrophils, Is Elevated in Serum of Patients with Community‐Acquired Pneumonia Requiring Hospitalization Julia S. Johansen, Peter Junker, Niels Borregaard, The Journal of Infectious Diseases	1999	120
A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value Søren Jacobsen, Jørgen Holm Petersen, Susanne Ullman, Clinical Rheumatology RheumatologyClinical FindingAutoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus Treatment	1998	116
Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia Rikke Leth‐Larsen, Ida Tornøe, Vivi Moeller, Clinical Immunology Community-acquired PneumoniaSurfactant Protein DImmunologyPulmonary Alveolar ProteinosisRespiratory Infection	2003	115

Page 1